Advertisement

Dilated, Restrictive/Infiltrative, and Hypertrophic Cardiomyopathies

  • Rory B. Weiner
  • Aaron L. Baggish
  • Aaron L. Baggish
Chapter
  • 2.8k Downloads

Abstract

Cardiomyopathies represent a heterogeneous group of heart muscle diseases that are a major cause of morbidity and mortality. Classification schemes for cardiomyopathy have been complex, and efforts have been made to classify the disease states based on myocardial characteristics and etiologies. The etiology, diagnosis, and management of dilated cardiomyopathy (DCM), restrictive/infiltrative cardiomyopathy, and hypertrophic cardiomyopathy (HCM) are the subject of this chapter and several features of each form of cardiomyopathy are highlighted in Table 17-1.

Keywords

Sudden Cardiac Death Implantable Cardioverter Defibrillator Arrhythmogenic Right Ventricular Cardiomyopathy Constrictive Pericarditis Cardiac Amyloidosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ACE

Angiotensin converting enzyme

AF

Atrial fibrillation

ANA

Anti-nuclear antibody

AR

Aortic regurgitation

ARB

Angiotensin receptor blocker

ARVC

Arrhythmogenic right ventricular cardiomyopathy

BNP

B-type natriuretic peptide

CAD

Coronary artery disease

CMV

Cytomegalovirus

CRT

Cardiac resynchronization therapy

CT

Computed tomography

CXR

Chest x-ray

DCM

Dilated cardiomyopathy

E’

Early peak diastolic tissue velocity

ECG

Electrocardiogram

HCM

Hypertrophic cardiomyopathy

HIV

Human immunodeficiency virus

HOCM

Hypertrophic obstructive cardiomyopathy

ICD

Implantable cardioverter defibrillator

LV

Left ventricle or left ventricular

LVEF

Left ventricular ejection fraction

LVH

Left ventricular hypertrophy

LVOT

Left ventricular outflow tract

MR

Mitral regurgitation

MRI

Magnetic resonance imaging

NTproBNP

N-terminal pro B-type natriuretic peptide

RV

Right ventricle or right ventricular

SAM

Systolic anterior motion

SCD

Sudden cardiac death

SPEP

Serum protein electrophoresis

Supplementary material

Video 17-1

DCM (AVI 14959 kb)

Video 17-2

Amyloid (AVI 17528 kb)

Video 17-3

HCM (AVI 9632 kb)

References

  1. 1.
    Watkins H, Ashrafian H, Redwood C. Inherited cardiomyopathies. N Engl J Med. 2011;364(17):1643–56.PubMedCrossRefGoogle Scholar
  2. 2.
    McMurray JJ. Systolic heart failure. N Engl J Med. 2010;362(3):228–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Maron BJ, Towbin JA, Gaetano T, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of cardiomyopathies. Circulation. 2006;113:1807–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119(14):e391–479.PubMedCrossRefGoogle Scholar
  6. 6.
    Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116(19):2216–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MRG, Towbin JA. Genetic evaluation of cardiomyopathy – a Heart Failure Society of America practice guideline. J Card Fail. 2009;15:83–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol. 2010;55(17):1769–79.PubMedCrossRefGoogle Scholar
  9. 9.
    Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Kim JS, Judson MA, Donnino R, Gold M, Cooper Jr LT, Prystowsky EN, et al. Cardiac sarcoidosis. Am Heart J. 2009;157(1):9–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000;101(21):2490–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br J Sports Med. 2009;43(9):649–56.PubMedCrossRefGoogle Scholar
  14. 14.
    Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010;121(3):445–56.PubMedCrossRefGoogle Scholar
  15. 15.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and ­treatment of hypertrophic cardiomyopathy. Circulation. 2011;124(24):2761–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Mitchell JH, Haskell W, Snell P, Van Camp SP. Task force 8: classification of sports. J Am Coll Cardiol. 2005;45(8):1364–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Chang SM, Nagueh SF, Spencer 3rd WH, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42(2):296–300.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Rory B. Weiner
    • 1
  • Aaron L. Baggish
    • 2
  • Aaron L. Baggish
    • 3
  1. 1.Harvard Medical School Cardiovascular Performance Program, Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Cardiovascular Performance Program, Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA

Personalised recommendations